Apellis Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 6, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-09-25

Reporting Person: Eisele Jeffrey (See Remarks)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$30.45	2030-08-31	Common Stock (125000)		Direct

Footnotes

F1: This stock option was granted on September 1, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.